The committee consists of 13 leading multinational companies from Canada, Europe, India, Israel, Japan, and the US
The International Generic and Biosimilar medicines Association (IGBA) has established a CEO Advisory Committee consisting of 13 leading multinational companies from Canada, Europe, India, Israel, Japan, and the US.
The committee members are:
Chirag Patel, President and Co-Chief Executive Officer – Amneal Pharmaceuticals.
Jeff Watson, President and Chief Executive Officer, Apotex.
Pankaj Patel, Chairman, Cadila Healthcare.
Samina Hamied, Executive Vice-Chairperson, Cipla.
Satish Reddy, Chairman, Dr Reddy’s Laboratories.
Lucas Sigman, Chief Executive Officer, Insud Pharma
Vinita Gupta, Chief Executive Officer, – Lupin
Richard Saynor, Chief Executive Officer, Sandoz
Peter Goldschmidt, Chief Executive Officer and Chairman Executive Board – STADA Arzneimittel
Dilip Shanghvi, Managing Director, Sun Pharmaceutical Industries
Kåre Schultz, President and Chief Executive Officer, Teva Pharmaceuticals Industries
David Peix, Chief Executive Officer, Towa Pharma International Holdings
Michael Goettler, Chief Executive Officer, Viatris
The committee provides a forum for industry leaders to discuss broad, strategic issues, and to engage and position the industry on a range of critical policy issues. “The establishment of this CEO Advisory Committee is transformative for our Association,” said Vivian Frittelli, IGBA Chair.
Suzette Kox, Secretary-General, IGBA added “This industry has lived up to the challenges posed by the pandemic. In many instances, there is now clear recognition that the generic and biosimilar medicines industry is the answer for affordable and sustainable solutions in such situations and beyond.”
